115 related articles for article (PubMed ID: 17929708)
1. [AL-amyloidosis and its treatment by eliminating the precursor protein].
Verbeek DE; Hazenberg BP; Jager PL; Kremer Hovinga TK
Ned Tijdschr Geneeskd; 2007 Sep; 151(37):2021-6. PubMed ID: 17929708
[TBL] [Abstract][Full Text] [Related]
2. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin-related (AL) amyloidosis.
Husby G
Clin Exp Rheumatol; 1983; 1(4):353-8. PubMed ID: 6442636
[TBL] [Abstract][Full Text] [Related]
4. Systemic immunoglobulin light-chain amyloidosis.
Comenzo RL
Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
Kourelis TV; Kumar SK; Go RS; Kapoor P; Kyle RA; Buadi FK; Gertz MA; Lacy MQ; Hayman SR; Leung N; Dingli D; Lust JA; Lin Y; Zeldenrust SR; Rajkumar SV; Dispenzieri A
Am J Hematol; 2014 Nov; 89(11):1051-4. PubMed ID: 25111004
[TBL] [Abstract][Full Text] [Related]
6. The challenge of systemic immunoglobulin light-chain amyloidosis (Al).
Palladini G; Comenzo RL
Subcell Biochem; 2012; 65():609-42. PubMed ID: 23225018
[TBL] [Abstract][Full Text] [Related]
7. Systemic light-chain amyloidosis presenting with rapid progressive heart failure.
Sunbul M; Durmus E; Kivrak T; Besiroglu F; Gerin F; Sari I; Mutlu B
Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):224-7. PubMed ID: 23868674
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
[TBL] [Abstract][Full Text] [Related]
10. Light-chain (AL) amyloidosis: diagnosis and treatment.
Sanchorawala V
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1331-41. PubMed ID: 17699366
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
12. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
13. A case of primary immunoglobulin light chain amyloidosis with a delayed appearance of Bence Jones protein in urine.
Kurusu A; Yamada T; Yamaji K; Nishitani M; Tashiro K; Maeda K; Horikoshi S; Shirato I; Rinno H; Tomino Y
Nephrology (Carlton); 2004 Jun; 9(3):122-5. PubMed ID: 15189172
[TBL] [Abstract][Full Text] [Related]
14. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
15. Analysis of clinical and pathological characteristics of 28 cases with renal amyloidosis.
Zhu X; Liu F; Liu Y; Liu H; Xu X; Peng Y; Sun L; Yuan S
Clin Lab; 2011; 57(11-12):947-52. PubMed ID: 22239026
[TBL] [Abstract][Full Text] [Related]
16. Primary amyloidosis (AL) as a cause of nephrotic syndrome.
Bataille Y; Bovy C; Lancellotti P; Melchior V; Delbecque K; Beguin Y; Krzesinski JM
Acta Clin Belg; 2005; 60(2):94-7. PubMed ID: 16082995
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
18. [Immunoglobulin amyloidosis].
Hermine O; Bourquelot P; Buzyn A; Aucouturier P
Rev Prat; 1997 Oct; 47(16):1787-91. PubMed ID: 9453204
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
20. [Current methods of systemic amyloidosis diagnosis and monitoring of its course].
Rameev VV; Kozlovskaia LV; Malinina EA; Serova AG; Kogarko IN; Kogarko BS; Liubimova NV
Ter Arkh; 2011; 83(8):48-54. PubMed ID: 21961333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
